Mast cell development is a complex process that results in the appearance of phenotypically distinct populations of mast cells in different anatomical sites . Mice homozygous for mutations at the W or Sl locus exhibit several phenotypic abnormalities, including a virtual absence of mast cells in all organs and tissues. Recent work indicates that Wencodes the c-kit tyrosine kinase receptor, whereas Sl encodes a c-kit ligand that we have designated stem cell factor (SCF). Recombinant or purified natural forms of the c-kit ligand induce proliferation of certain mast cell populations in vitro, and injection of recombinant SCF permits mast cells to develop in mast cell-deficient WCB6Ft-SI/Sld mice. However, the effects of SCF on mast cell proliferation, maturation, and phenotype in normal mice in vivo were not investigated . We now report that local administration of SCF in vivo promotes the development of connective tissue-type mast cells (CTMC) in the skin of mice and that systemic administration of SCF induces the development of both CTMC and mucosal mast cells (MMC) in rats. Rats treated with SCF also develop significantly increased tissue levels of specific rat mast cell proteases (RMCP) characteristic of either CTMC (RMCP I) or MMC (RMCP II). These findings demonstrate that SCF can induce the expansion of both CTMC and MMC populations in vivo and show that SCF can regulate at least one cellular lineage that expresses c-kit, the mast cell, through complex effects on proliferation and maturation.
S tudies in mice and rats indicate that mast cells are derived from hematopoietic precursors that arise in the bone marrow and circulate in the blood, but complete their program of differentiation and maturation within interstitial tissues, epithelia, or serosal cavities (reviewed in references [1] [2] [3] [4] [5] [6] . In murine rodents, this process results in the generation of at least two distinct mast cell populations that vary in many aspects ofphenotype, the connective tissue-type mast cells (CTMC)t, which occur in such sites as the skin and peritoneal cavity, and the mucosal mast cells (MMC), which occur in the mucosa of the gastrointestinal tract (reviewed in references 1-4). Evidence derived from both in vitro and in vivo studies indicates that IIr3 represents one major growth 1 Abbreviations used in this paper. BrdU, 5-bromo-2'-deoxyuridine ; CTMC, connective tissue-type mast cell; Hct, hematocrit ; MMC, mucosal mast cell ; PMC, peritoneal mast cell ; RMCP, rat mast cell protease ; rrSCF 164 , recombinant rat stem cell factort64 . factor for MMC, whereas the regulation of CTMC proliferation requires additional and/or alternative factors (reviewed in references [1] [2] [3] [4] [5] [6] . For example, in vitro work indicates that one representative CTMC, peritoneal mast cells (PMC), do not proliferate in response to IIr3 alone but divide when 11,3 is provided with a second stimulus such as IIT4 (7) or PMA (8) .
Several important insights into mast cell development have been derived from analyses of mice that virtually lack mast cells as a result of a double dose of mutant genes at either the W locus on chromosome 5 or the SI locus on chromosome 10 (reviewed in references 1, 2, and 5). For example, W or Sl mutant mice lack both CTMC and MMC, indicating that the W or Sl gene products are important in the development of both of these mast cell populations in vivo (reviewed in references 1, 2, 5, and 6). Moreover, both in vitro and in vivo studies suggested that the mast cell deficiencies of these mutant mice reflected, in the case of W mutants, defects in the responsiveness of cells in the mast cell lineage to a stromal cell-derived growth factor and, in the case ofSl mutants, inadequate production of this growth factor by stromal cells (reviewed in references 1, 2, and 5).
The products encoded at W and Sl recently have been defined. W encodes the c-kit tyrosine kinase growth factor receptor (9, 10) , whereas Sl encodes a newly recognized multifunctional growth factor that represents a ligand for c-kit (11) (12) (13) (14) (15) (16) (17) (18) . Several lines of evidence in addition to the lack of mast cells in W or Sl mutant mice indicate that one of the important biological activities of the c-kit ligand is to regulate mast cell development . The recombinant c-kit ligand can promote the proliferation of certain populations of immature, IIr3-dependent mast cells in vitro (11, 14, 15, 17, 18) , and the c-kit ligand purified from the supernatants of BALB/3T3 fibroblasts (19) , or the recombinant ligand (20) , can induce proliferation of IL-3-independent mouse PMC in vitro. In addition, we demonstrated that daily subcutaneous injection of a recombinant c-kit ligand, recombinant rat stem cell factor 164 (rrSCF164 ), for 3 wk permitted mast cells to develop in the skin of genetically mast cell-deficient WCB6F1-Sl/Sld mice (16) . However, the mast cells that developed in WCB6Ft-Sl/Sld mice injected with rrSCF 164 were not characterized according to phenotype. Nor was it determined whether rrSCF 164 could influence mast cell development or phenotype in normal mice. In the present study, we therefore examined the effects of rrSCF164 on mast cell populations in normal mice and rats in vivo, using approaches that permitted the anatomical and phenotypic characterization of the responding cells as CTMC or MMC. Some ofthese results have been reported in abstract form (20) .
Materials and Methods
Studies in Mice. Groups of five to seven female 8-12-wk-old WCB6F,-+/+, WCB6F,-Sl/Sld, WBB6F,-+/+, and WBB6F,-WlWv mice (The Jackson Laboratory, Bar Harbor, ME) received for 3 wk a daily subcutaneous injection of rrSCF161 purified from Escherichia coli and modified by the covalent attachment ofpolyethylene glycol (16) or vehicle alone (0, 30, or 100 Rg rrSCF 16^/kg in 150-200 Ftl of sterile saline containing 0.1% BSA) (fraction V, fatty acid free; ICN Immunobiologicals, Lisle, IL) . Injections were performed with the mice under light ether anesthesia and were delivered to approximately the same site on the dorsal back skin. Blood for determination of hematocrit (Hct) was obtained from the mice by retroorbital puncture under light ether anesthesia on the day before initiation of treatment and on the day ofdeath. For labeling of tissue mast cells proliferating in vivo (21), 5-bromo-2'-deoxyuridine (BrdU) (Sigma Chemical Co., St. Louis, MO) was injected intraperitoneally (100 mg/kg in sterile saline) 1 h before death . After death by cervical dislocation, the cutaneous injection site was excised and fixed in Carnoy's fixative, and embedded in paraffin. 4-um sections were cut, placed onto polylysine-coated slides, and processed as in reference 21 for staining of mast cells with 1.0% alcian blue, pH 1.0, and for immunohistochemical staining of BrdU-labeled nuclei, using an anti-BrdU mAb (Becton Dickinson & Co., Mountain View, CA) . The slides were examined at 400x to quantify mast cells/mm' of dermis (22) and to determine the percent of mast cells positive for BrdU incorporation (21) . Other slides ofthe Camoy's-fixed specimens were stained with the heparin-binding fluorescent dye berberine sulfate (23) or 126 The Rat c-kit Ligand Induces Development of Mast Cells with alcian blue/safranin, and were examined in an epifluorescent or light microscope, respectively, as previously described (1, 22) . Studies in Rats. Groups of five to eight female 16-wk-old Wistar rats received 14-d daily intravenous injections of either rrSCF'64 (25 wg/kg/d in 1.0 ml of sterile, pyrogen-free 0.9% NaCl "saline") or 1.0 ml of saline alone. 24 h after the last injection, the rats were killed by exsanguination under deep ether anesthesia, and samples of tissues were fixed in 4.0% paraformaldehyde, processed into paraffin, and assessed in sections stained with 0.5% toluidine blue at pH 0.5 for 2 h (24). Mast cells were quantified at 400x, and the results were expressed as no. (mean ± SEM)/mmz of tissue (22) . Other samples of the same tissues were processed as described (24) for determination of content ofrat mast cell protease I (RMCP I) and RMCP II by ELISA, and the results were expressed as micrograms protease (mean ± SEM)/gram of tissue. The bone marrow cells were harvested from a single femur of each rat by flushing the marrow cavity with 0.9% NaCl and then washing the cells three times with HBSS/5% FCS (HBSS/FCS). The peritoneal lavage cells ofeach rat were obtained by lavaging each peritoneal cavity with 20 ml of HBSS/FCS and then washing the cells three times with HBSS/FCS. Aliquots of the total femoral bone marrow cells and peritoneal lavage cells were diluted 1:10 in methylene blue/propylene glycol for counting the numbers of total cells and mast cells in each preparation, the remainder of the femoral blue marrow or peritoneal cells were used for determination of RMCP I and 11 content by ELISA (24) .
Results and Discussion
Local Administration ofSCF Induces the c-kit-dependent Development of CTMC in the Skin ofMice. Recombinant rat SCF 164 administered in daily subcutaneous injections for 3 wk induced a striking expansion ofdermal mast cell populations in normal WBB6F1-+/+ or WCB6F1-+/+ mice, and in genetically mast cell-deficient WCB6F1-Sl/Sld mice (Table  1) . In WBB6F1-+/+ mice, mast cell numbers at sites injected with 100 or 30 hg of rrSCF164 /kg were 166 or 15 times that in control sites injected with vehicle alone. In striking contrast to its effects on populations of dermal mast cells, rrSCFlsa had little or no effect on the Hct of normal mice of either genotype tested ( Table 1) .
The majority of the mast cells at rrSCF 161 injection sites, like dermal CTMC in the skin of untreated normal mice (1, 22) , exhibited cytoplasmic reactivity with the heparin-binding fluorescent dye berberine sulfate, and many of them stained with safranin ( Fig. 1, A, B, D , and E). Thus, injection of rrSCF 164 as the sole exogenous cytokine resulted in the development ofdermal mast cells with characteristics ofCTMC. Colocalization of immunohistochemical staining for BrdU incorporated into nuclear DNA and mast cell cytoplasmic granule staining with alcian blue (21) indicated that morphologically identifiable mast cells were proliferating at sites of rrSCF 164 injection (Table 1 and Fig. 1 F) . This finding indicated that the increased numbers of mast cells at sites of rrSCF 164 injection reflected at least in part the proliferation of differentiated dermal mast cells, not merely the proliferation and/or maturation of mast cell precursors.
However, the skin of Sl/Sld mice ordinarily contains virtually no dermal mast cells (Table 1 and reference 25) . Thus, even though many differentiated mast cells were proliferating 
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at rrSCFt64 injection sites in Sl/Sld mice 3 wk after initiation of treatment (Table 1) , some of the effect of rrSCF 164 in these mice must have reflected the recruitment, proliferation, and/or induction of maturation of the mast cell precursors present in these animals (25) . An effect of rrSCF 164 on mast cell maturation is also supported by the finding that many of the mast cells at rrSCF 164 injection sites in Sl/Sld mice stained with berberine sulfate (Fig. 1 C) or safranin (data not shown), and by data indicating that rrSCFt 64 can induce 11, 3-dependent bone marrow-derived cultured mast cells to mature and acquire phenotypic characteristics of CTMC in vitro (20, 26) . In contrast to the effects of rrSCF 114 in Sl/Sld mice, injection of rrSCF 164 into genetically mast cell-deficient WBB6F,-W/ W°mice influenced neither the profound mast cell deficiency, nor the anemia, of these animals ( Table 1) . This result, together with work indicating that the W and W°alleles encode c-kit products that express no (W) or markedly diminished (W°) tyrosine kinase activity (27) , indicates that the ability of rrSCF164 t o induce the development of dermal CTMC in vivo requires that the rrSCF 164 interacts with a functionally active c-kit receptor. The complete failure of even very high doses of rrSCF 164 t o induce cutaneous mast cell development in W/W°mice is also noteworthy in light of reports that this mutant can develop mature dermal mast cells in association with a chronic idiopathic dermatitis (22) , in response to repeated epicutaneous applications of PMA (28), or as a result of treatment with 1173 (29) . The results reported here indicate that the appearance of mast cells in the skin of W/W°mice in these settings probably does not reflect increased local production of endogenous c-kit ligand, but instead may be due to other (Table  1) , the effects of rrSCF164 on mast cell populations were most striking in the vicinity of the subcutaneous injection sites. For example, no mast cells appeared in the skin contralateral to rrSCF164 injection sites in Sl/Sld mice or in the gastric tissues of these animals (data not shown) . To assess the systemic effects of rrSCF164 on mast cell development and phenotype, we turned to the rat . Daily intravenous injections are more readily performed in rats than in mice. More importantly, Huntley et al. (24) have reported highly sensitive and specific ELISA methods for quantifying tissue content of mast cell-specific proteases associated with CTMC 12 8 The Rat c-kit Ligand Induces Development of Mast Cells and MMC (RMCP I and RMCP II, respectively) in this species . We found that daily intravenous administration of rrSCF164 to rats at a dose of 25 Ag/kg/d for 14 d increased mast cell levels systemically and also produced striking increases in levels of both types of rat mast cell-associated proteases (Tables 2 and 3 ). In the skin, lung, and liver (Table  2) , rrSCF 164 treatment resulted in marked increases in numbers of mast cells and in tissue content of the CTMCassociated protease, RMCP 1, but no significant changes in levels of the MMC-associated protease, RMCP II. In the spleen, bone marrow, and peritoneal cavity (Tables 2 and 3) , rrSCF 164 treatment resulted in striking expansion of mast cell populations, as well as marked increases in levels ofboth RMCP I and RMCP Il. Note, however, that the total amounts of RMCP II in these sites in the rrSCF164-treated animals were much less than the corresponding amounts of RMCP 1. rrSCF164 treatment significantly expanded populations of mast cells in the mucosa, submucosa, and muscularis propria of the glandular stomach, and in the mucosa and submucosa of the ileum (Table 2 ) . MMC predominate in the mucosa of these organs, whereas CTMC predominate in the submucosa and muscularis propria (3, 4, 24) . rrSCFt64 treatment increased the content of both RMCP II (p = 0.018 by the two-tailed Student's t test) and RMCP I (p = 0.045 by the one-tailed Student's t test) in the glandular stomach, and also significantly increased the content of both proteases in the ileum (Table 2) . Thus, according to anatomical distribution and mast cell protease phenotype (reviewed in references 3-5 and 24), intravenous administration of rrSCFt64 to rats markedly expanded populations of CTMC and also increased levels of gastrointestinal MMC . By immunohistochemistry (24) , mast cells in rrSCFtb4-treated rats exhibited a pattern of staining for RMCP I and II that was similar to that of mast cells in control rats (24) . For example, dermal mast cells were exclusively RMCP I+ and RMCP II -, whereas mast cells in the mucosa of the ileum were predominantly RMCP II+ and RMCP I -. However, the effect of rrSCF164 treatment on the numbers of mast cells in various sites generally was more marked than the corresponding effect on RMCP content . For example, in the spleen, femoral bone marrow, and glandular stomach, mast cell numbers were -3,000, 13, and 3 times those in control rats, whereas the corresponding ratios for total content of RMCP I and II in rrSCFtb 4-treated vs. control rats were ti130, 5, and 1.5. This finding may reflect any of a 129
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These data (mean ± SEM) are from the same rats shown in These data show that the local injection of SCF promoted the expansion of dermal CTMC populations in mice in vivo, and indicate that this effect required a functionally active c-kit receptor. In rats, intravenous administration of rrSCFt64 resulted in striking expansions of mast cell populations in all of the anatomical sites examined . These included sites that usually contain large populations of CTMC, such as the skin and peritoneal cavity, and sites that ordinarily contain substantial numbers of MMC, such as the mucosa of the glandular stomach and ileum . These findings, taken together with the observation that W/W°and Sl/Sld mice virtually lack both CTMC and MMC (1, 2, 6) , indicate that interactions between c-kit and its ligand importantly regulate the normal development ofboth CTMC and MMC . However, administration of exogenous SCF not only produced significant expansions of populations of CTMC and MMC in sites ordinarily containing large numbers of mast cells, such as the skin and stomach, but also resulted in the appearance of many mast cells at sites that typically contain very few mast cells, such as the liver, spleen, and bone marrow. These findings raise the possibility that the mast cell proliferation associated with certain immunological or pathological responses may reflect, in part, excessive local or even systemic production of c-kit ligand.
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